Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

Fabry sygdom guide

Har du spørgsmål til Fabry sygdom?

Číst více

Dự Phòng Thuyên Tắc Huyết Khối Tĩnh Mạch Trên Bệnh Nhân Chấn Thương Nặng, Đa Chấn Thương Theo Hướng Dẫn Điều Trị Của Bộ Y Tế 2023

Číst více

BR1DGE Symposium at EASD 2024

At the BR1DGE symposium at EASD 2024, leading experts shared new insights on early-stage (Stage 1 and 2) autoimmune type 1 diabetes (T1D), emphasizing the importance of screening for islet antibodies (IAbs) together with monitoring and education. Early type 1 diabetes identification can help to prepare people for a life with T1D.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Číst více

Advances in the biology of chronic GVHD

Číst více

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Číst více

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Číst více

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Číst více

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Číst více

Advances in the biology of chronic GVHD

Číst více

Cập Nhật Nghiên Cứu SOLI-D

Číst více

Congreso Argentino de Diabetes 2024

Este año 2024, la SAD celebró su 70° aniversario y la Escuela de Graduados su 50° aniversario. Contó con una excelente convocatoria con la participación de más de 3000 profesionales y un programa de excelencia. A continuación, vamos a destacar algunos de los temas que se trataron.

Číst více

Fexofenadina: El Secreto para Mejorar tu Calidad de Vida

La fexofenadina (Allegra®) antihistamínico de segunda generación aprobado por la FDA para tratar la rinitis alérgica. Actúa bloqueando los receptores H1, para prevenir que la histamina se adhiera, reduciendo la liberación de mediadores inflamatorios y aliviando síntomas como estornudos, picazón, rinorrea y congestión nasal.

Číst více